NOT FOR DISTRIBUTION
Header cover image

Market Cap

AU$19.8m

Last Updated

2021/05/18 08:29 UTC

Data Sources

Company Financials +

Executive Summary

Oventus Medical Limited, a medical device company, develops and commercializes oral appliances for the treatment of obstructive sleep apnoea (OSA) and snoring in Australia, Canada, and the United States. More Details


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has Oventus Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OVN is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: OVN's weekly volatility (11%) has been stable over the past year.


Market Performance


7 Day Return

-7.4%

OVN

-2.1%

AU Medical Equipment

-2.2%

AU Market


1 Year Return

-51.0%

OVN

14.3%

AU Medical Equipment

33.8%

AU Market

Return vs Industry: OVN underperformed the Australian Medical Equipment industry which returned 14.3% over the past year.

Return vs Market: OVN underperformed the Australian Market which returned 33.8% over the past year.


Shareholder returns

OVNIndustryMarket
7 Day-7.4%-2.1%-2.2%
30 Day-37.5%-3.7%-1.0%
90 Day-40.5%0.2%1.0%
1 Year-51.0%-51.0%15.3%14.3%38.1%33.8%
3 Year-62.8%-63.2%27.1%21.6%30.2%14.7%
5 Yearn/a79.8%67.4%63.5%31.9%

Long-Term Price Volatility Vs. Market

How volatile is Oventus Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Oventus Medical undervalued compared to its fair value and its price relative to the market?

2.41x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OVN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OVN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OVN is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: OVN is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OVN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OVN is good value based on its PB Ratio (2.4x) compared to the AU Medical Equipment industry average (6.3x).


Future Growth

How is Oventus Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

52.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OVN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OVN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OVN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OVN's revenue (112.1% per year) is forecast to grow faster than the Australian market (4.9% per year).

High Growth Revenue: OVN's revenue (112.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: OVN is forecast to be unprofitable in 3 years.


Past Performance

How has Oventus Medical performed over the past 5 years?

-21.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OVN is currently unprofitable.

Growing Profit Margin: OVN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OVN is unprofitable, and losses have increased over the past 5 years at a rate of 21.2% per year.

Accelerating Growth: Unable to compare OVN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OVN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31.7%).


Return on Equity

High ROE: OVN has a negative Return on Equity (-117.77%), as it is currently unprofitable.


Financial Health

How is Oventus Medical's financial position?


Financial Position Analysis

Short Term Liabilities: OVN's short term assets (A$5.8M) exceed its short term liabilities (A$2.3M).

Long Term Liabilities: OVN's short term assets (A$5.8M) exceed its long term liabilities (A$515.1K).


Debt to Equity History and Analysis

Debt Level: OVN is debt free.

Reducing Debt: OVN has no debt compared to 5 years ago when its debt to equity ratio was 62%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OVN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: OVN has less than a year of cash runway if free cash flow continues to reduce at historical rates of 12.8% each year


Dividend

What is Oventus Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OVN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OVN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OVN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OVN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OVN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Chris Hart

2.75yrs

Tenure

AU$941,425

Compensation

Dr. Christopher Patrick Hart, also known as Chris, has been Chief Executive Officer and Managing Director of Oventus Medical Limited since August 30, 2018. Dr. Hart is the Co-Founder of Oventus Medical Lim...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD731.89K) is above average for companies of similar size in the Australian market ($USD287.85K).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: OVN's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: OVN's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: OVN insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.8%.


Top Shareholders

Company Information

Oventus Medical Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Oventus Medical Limited
  • Ticker: OVN
  • Exchange: ASX
  • Founded: 2015
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$19.783m
  • Shares outstanding: 158.26m
  • Website: https://o2vent.com

Location

  • Oventus Medical Limited
  • 1 Swann Road
  • Suite 1
  • Indooroopilly
  • Queensland
  • 4068
  • Australia

Listings


Biography

Oventus Medical Limited, a medical device company, develops and commercializes oral appliances for the treatment of obstructive sleep apnoea (OSA) and snoring in Australia, Canada, and the United States. T...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/18 08:29
End of Day Share Price2021/05/18 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.